Kathleen Stapleton
Adult Health · Watervliet, NYNPI 1174757397
Payments from drug & device makers
Across 114 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$414
- GSK$315
- Lilly USA, LLC$268
- AbbVie$261
- AstraZeneca$203
- Dexcom, Inc.$150
- plus $702 from 11 others
What the payments were for
- Food & beverage$2,313100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $414 |
| GSK | 13 | $315 |
| Lilly USA, LLC | 13 | $268 |
| AbbVie | 14 | $261 |
| AstraZeneca | 12 | $203 |
| Dexcom, Inc. | 7 | $150 |
| Renalytix AI, Inc. | 9 | $146 |
| Amgen | 7 | $129 |
| Bayer | 6 | $123 |
| Astellas Pharma US Inc | 3 | $86 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| Boehringer Ingelheim | 2 | $34 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Exact Sciences | 1 | $26 |
| Merck | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Vertex | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$123
How this compares
$2,313 in reported general payments places this provider in the 80th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $90,540 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $24,123 |
| JardianceEmpagliflozin | 17 | $20,229 |
| EliquisApixaban | 22 | $15,301 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $2,315 |
| Gabapentin | 94 | $931 |
| Buspirone Hcl | 31 | $919 |
| Diclofenac Sodium | 29 | $905 |
| Levothyroxine Sodium | 66 | $617 |
| Famotidine | 70 | $574 |
| Nifedipine ErNifedipine | 11 | $548 |
| Atorvastatin Calcium | 59 | $513 |
| Omeprazole | 51 | $506 |
| Metoprolol Succinate | 39 | $445 |
| Fluticasone Propionate | 33 | $431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $414 | $90,54066 claims |
| GSKTrelegy Ellipta | $315 | $24,12334 claims |
| Boehringer IngelheimJardiance | $34 | $20,22917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,828 adult health providers in New York.
Other adult health in Watervliet
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.